What Has Been The Evolution of the Orlistat Market in Recent Years?
The orlistat market has seen considerable growth due to a variety of factors.
• The orlistat market has grown steadily in recent years. It will increase from $3.03 billion in 2024 to $3.24 billion in 2025, at a compound annual growth rate (CAGR) of 6.7%.
Factors driving growth include greater awareness of obesity-related health risks, the availability of orlistat in over-the-counter doses, prescription approvals, physician recommendations, and rising obesity-related healthcare costs.
How Will the Orlistat Market?
The orlistat market is expected to maintain its strong growth trajectory in upcoming years.
• The orlistat market is expected to reach $4.15 billion by 2029, growing at a CAGR of 6.4%.
This growth is attributed to increased healthcare spending on obesity treatments, sedentary lifestyles, government weight-loss programs, an aging population, and a shift from prescriptions to over-the-counter products. Trends include AI-driven diet plans, telehealth services, medication adherence tracking devices, and digital therapeutics.
Which Factors Are Boosting Growth In The Orlistat Market?
The escalation in obesity statistics is anticipated to fuel the expansion of the orlistat market. Obesity, a health condition marked by an excess accumulation of body fat that can negatively affect health status, can typically be identified by a body mass index (BMI) of 30 or above. The rise in this condition is attributed to elements such as imbalanced diet, inadequate physical exercise, and sedentary living habits. Orlistat aids in managing obesity by preventing the assimilation of dietary fats, which in turn assists in weight reduction and weight loss maintenance. It's commonly advised in conjunction with a low calorie diet and workout for more favorable outcomes. For example, in March 2022, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, stated that more than 1 billion people worldwide were suffering from obesity, including 650 million adults, 340 million teenagers, and 39 million children. This statistic is steadily growing and it's estimated that by 2025 around 167 million individuals, encompassing both adults and kids, will be affected by health complications due to overweight or obesity. Thus, the escalating rates of obesity are serving as a key driver for the development of the orlistat market.
What Key Areas Define The Segmentation Of The Global Orlistat Market?
The orlistat market covered in this report is segmented –
1) By Type: 120 Milligram (Mg), 60 Milligram(Mg)
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By Application: Weight-Reducing Aid, Other Applications
Subsegments:
1) By 120 Milligram (Mg): Prescription-Based 120 Mg Orlistat, Over-The-Counter (OTC) 120 Mg Orlistat
2) By 60 Milligram (Mg): Over-The-Counter (OTC) 60 Mg Orlistat, Prescription-Based 60 Mg Orlistat
Pre-Book The Orlistat Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Orlistat Market?
Key players in the orlistat market are focusing on the creation of innovative items such as weight reduction medications, leveraging advanced approaches and designs to improve personal hygiene and comfort. Weight reduction drugs are tailored to assist individuals in shedding excessive body weight through appetite suppression, metabolism enhancement, or hindrance of fat absorption. For example, Eli Lilly and Company, a pharmaceutical firm based in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) for Zepbound (tirzepatide) injection, a novel weight loss medication, in November 2023. This is the first and only sanctioned treatment that triggers two incretin hormone receptors, GIP and GLP-1, aiming at a root cause of surplus weight. Zepbound is prescribed for usage in conjunction with a calorie-decreased diet and augmented physical activity for long-term weight control in adults suffering from obesity (BMI =30 kg/m²) or overweight (BMI =27 kg/m²) conditions linked to weight.
Who Are the Key Players In The Orlistat Market?
Major companies operating in the orlistat market are:
• Merck & Co. Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Roche Holding AG
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Intas Pharmaceuticals Ltd.
• Lupin Pharmaceuticals Inc.
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Macleods Pharmaceuticals Ltd.
• Zydus Life
• Emcure Pharmaceuticals Ltd.
• Lannett Company Inc.
• Strides Pharma Science Ltd.
• Indoco Remedies Ltd.
• Wockhardt Ltd.
• Jubilant Life Sciences Ltd.
What Is The Most Dominant Region In The Orlistat Market?
North America was the largest region in the orlistat market in 2023. The regions covered in the orlistat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
